AZD1152 in patients with Advanced Solid Malignancies-Study 3
Study identifier:D1531C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a continuous 7-day Intravenous Infusion in Patients With Advanced Solid Malignancies
Medical condition
Solid tumours
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1152
Sex
All
Actual Enrollment
45
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2006
Primary Completion Date: -
Study Completion Date: 01 Jul 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
David Kerr
University of Oxford
